65,437 trials
Primary Biliary Cholangitis
Primary: Risk of the First Event of the Composite Events — 8; 32 Events during the study period — p=<.001
Polypharmacy · Surgical Procedure, Operative · Morality
Primary: Mortality — 4356; 1919 Participants
Healthy
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) After a Single Dose of CD388 — 5; 5; 5; 8 Participants
Metastasis From Malignant Tumor of Prostate (Disorder)
Primary: Region-Level Correct Localization Rate (CLR) — 86.67; 86.67; 76.67; 80.00 percentage of Regions
Anxiety · Preoperative Anxiety
Primary: Change in the Anxiety Score Using the Visual Analogue Score for Anxiety Between Treatment Arms — 0; 0; 0 score on a scale
Dementia
Primary: Cognitive Function (PWCI, Direct Assessment) — 31.78; 32.60 units on a scale
Diffuse Large B-Cell Lymphoma
Primary: Overall Survival in Subjects Who Possess the DGM1™ Biomarker — 82; 87 percentage of patients
Mild Cognitive Impairment · Dementia
Primary: Treatment-emergent Adverse Events — 19; 20 Participants
Insomnia
Primary: Insomnia Severity Index (ISI) — 17.0; 18.9; 7.3; 10.9 score on a scale
Ileostomy - Stoma · Colostomy Stoma
Primary: Emotional Impact Score (Scale From 0-100) — 73.4; 62.0 score on a scale — p=<0.001
Insomnia Chronic
Primary: CSF Markers Related to Dementia — 4332.1; 4824.0; 393.2; 419.4 picograms per milliliter
Development of LIFU for Clinical Purposes
Primary: Waveforms — 1.06; 1.10; 0.97; 0.99 percentage of baseline MEP mV
Heart Failure
Primary: Change in Left Ventricle End-Systolic Volume Index (LVESVI) — -11.6; -4.1 mL/m^2 — p=0.0001
Carcinoma, Non-Small-Cell Lung
Primary: Percentage of Participants With Adverse Events — 564 Participants
Schizophrenia · Psychosis · Schizoaffective Disorder
Primary: Speed of Processing From the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) — 41.75; 41.2; 24.82…